184 related articles for article (PubMed ID: 21068290)
1. Breakthrough Hormographiella aspergillata infections arising in neutropenic patients treated empirically with caspofungin.
Suarez F; Olivier G; Garcia-Hermoso D; Randriamalala E; Ghez D; Bruneau J; Kauffmann-Lacroix C; Bougnoux ME; Lortholary O
J Clin Microbiol; 2011 Jan; 49(1):461-5. PubMed ID: 21068290
[TBL] [Abstract][Full Text] [Related]
2. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
Moen MD; Lyseng-Williamson KA; Scott LJ
Drugs; 2009; 69(3):361-92. PubMed ID: 19275278
[TBL] [Abstract][Full Text] [Related]
3. An open study of the comparative efficacy and safety of caspofungin and liposomal amphotericin B in treating invasive fungal infections or febrile neutropenia in patients with haematological malignancy.
Ellis M; Frampton C; Joseph J; Alizadeh H; Kristensen J; Hauggaard A; Shammas F
J Med Microbiol; 2006 Oct; 55(Pt 10):1357-1365. PubMed ID: 17005784
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of caspofungin versus liposomal amphotericin B for empiric antifungal treatment in patients with neutropenic fever in Italy.
Stam WB; Aversa F; Kumar RN; Jansen JP
Value Health; 2008; 11(5):830-41. PubMed ID: 18494752
[TBL] [Abstract][Full Text] [Related]
5. Caspofungin versus liposomal amphotericin B: are they really comparable?
Sekine L; Humbwavali J; Wolff FH; Barcellos NT
Pediatr Infect Dis J; 2010 Oct; 29(10):985-6; author reply 986-7. PubMed ID: 20859182
[No Abstract] [Full Text] [Related]
6. Combined medico-surgical strategy for invasive sino-orbito-cerebral breakthrough fungal infection with Hormographiella aspergillata in an acute leukaemia patient.
Heiblig M; Bozzoli V; Saison J; Thomas X; De Croze D; Traverse-Glehen A; Cosmidis A; Chidiac C; Ferry T; Alanio A; Bienvenu AL; Dupont D; Ducastelle-Lepretre S; Michallet M; Ader F;
Mycoses; 2015 May; 58(5):308-12. PubMed ID: 25752189
[TBL] [Abstract][Full Text] [Related]
7. Economic impact of caspofungin as compared with liposomal amphotericin B for empirical therapy in febrile neutropenia in Australia.
Al-Badriyeh D; Liew D; Stewart K; Kong DC
J Antimicrob Chemother; 2009 Jun; 63(6):1276-85. PubMed ID: 19346292
[TBL] [Abstract][Full Text] [Related]
8. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
Walsh TJ; Teppler H; Donowitz GR; Maertens JA; Baden LR; Dmoszynska A; Cornely OA; Bourque MR; Lupinacci RJ; Sable CA; dePauw BE
N Engl J Med; 2004 Sep; 351(14):1391-402. PubMed ID: 15459300
[TBL] [Abstract][Full Text] [Related]
9. A prospective, randomized study of empirical antifungal therapy for the treatment of chemotherapy-induced febrile neutropenia in children.
Caselli D; Cesaro S; Ziino O; Ragusa P; Pontillo A; Pegoraro A; Santoro N; Zanazzo G; Poggi V; Giacchino M; Livadiotti S; Melchionda F; Chiodi M; Aricò M
Br J Haematol; 2012 Jul; 158(2):249-255. PubMed ID: 22571507
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia.
Maertens JA; Madero L; Reilly AF; Lehrnbecher T; Groll AH; Jafri HS; Green M; Nania JJ; Bourque MR; Wise BA; Strohmaier KM; Taylor AF; Kartsonis NA; Chow JW; Arndt CA; DePauw BE; Walsh TJ;
Pediatr Infect Dis J; 2010 May; 29(5):415-20. PubMed ID: 20431381
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis.
Kubiak DW; Bryar JM; McDonnell AM; Delgado-Flores JO; Mui E; Baden LR; Marty FM
Clin Ther; 2010 Apr; 32(4):637-48. PubMed ID: 20435233
[TBL] [Abstract][Full Text] [Related]
12. Caspofungin: antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis.
van Vianen W; de Marie S; ten Kate MT; Mathot RA; Bakker-Woudenberg IA
J Antimicrob Chemother; 2006 Apr; 57(4):732-40. PubMed ID: 16464895
[TBL] [Abstract][Full Text] [Related]
13. Breakthrough Invasive Sinusitis by Hormographiella aspergillata in a Neutropenic Patient Receiving Voriconazole Therapy: A Case Report and Review of Breakthrough H. aspergillata Infections.
Florez-Riaño AF; Ramírez-Sánchez IC
Mycopathologia; 2023 Aug; 188(4):401-407. PubMed ID: 37389746
[TBL] [Abstract][Full Text] [Related]
14. High rate of breakthrough invasive aspergillosis among patients receiving caspofungin for persistent fever and neutropenia.
Lafaurie M; Lapalu J; Raffoux E; Breton B; Lacroix C; Socié G; Porcher R; Ribaud P; Touratier S; Molina JM
Clin Microbiol Infect; 2010 Aug; 16(8):1191-6. PubMed ID: 19735276
[TBL] [Abstract][Full Text] [Related]
15. Hormographiella aspergillata pulmonary infections: Detection and identification of the fungus using pan-fungal PCR assays and DNA sequencing.
Nevez G; Guillerm G; Talarmin JP; Quinio D; Iriart X; Lissillour PL; Rezig S; Fangous MS; Ranty M; Bodenes L; Aubron C; Couturier MA; Le Gal S
J Mycol Med; 2024 Mar; 34(1):101463. PubMed ID: 38342037
[TBL] [Abstract][Full Text] [Related]
16. Rare severe mycotic infections in children receiving empirical caspofungin treatment for febrile neutropenia.
Yilmaz Karapinar D; Karadaş N; Önder Siviş Z; Yazici P; Duyu M; Metin D; Karapinar B; Aydinok Y
Braz J Infect Dis; 2015; 19(5):549-52. PubMed ID: 26275731
[TBL] [Abstract][Full Text] [Related]
17. Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients.
Chou LS; Lewis RE; Ippoliti C; Champlin RE; Kontoyiannis DP
Pharmacotherapy; 2007 Dec; 27(12):1644-50. PubMed ID: 18041885
[TBL] [Abstract][Full Text] [Related]
18. Caspofungin versus liposomal amphotericin B for empirical therapy.
Jones BL; McLintock LA
N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675090
[No Abstract] [Full Text] [Related]
19. Impact of alternate definitions of fever resolution on the composite endpoint in clinical trials of empirical antifungal therapy for neutropenic patients with persistent fever: analysis of results from the Caspofungin Empirical Therapy Study.
de Pauw BE; Sable CA; Walsh TJ; Lupinacci RJ; Bourque MR; Wise BA; Nguyen BY; DiNubile MJ; Teppler H
Transpl Infect Dis; 2006 Mar; 8(1):31-7. PubMed ID: 16623818
[TBL] [Abstract][Full Text] [Related]
20. Caspofungin: a major breakthrough in treatment of systemic fungal infections.
Agarwal MB; Rathi SA; Ratho N; Subramanian R
J Assoc Physicians India; 2006 Dec; 54():943-8. PubMed ID: 17334012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
